DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

DexCom (NASDAQ:DXCM – Free Report) had its price objective increased by Sanford ... Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share ...

DexCom (NASDAQ:DXCM – Free Report) had its price objective boosted by Wells Fargo ... Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom ...

Analyst Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report) and keeping the price target at ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target ...

Sensor and other revenues (96 ... The introduction of sensors like G6 and G7 in international markets also fueled revenue growth. Dexcom anticipates strong growth from its recent product launches ...

DXCM's third-quarter 2024 earnings and revenues surpass expectations, fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets. DexCom stock was falling Friday ...

DexCom, Inc. DXCM is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported ...

Pre-earnings options volume in DexCom (DXCM) is 1.6x normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 9.0%, or $6.67, after results are released.

DexCom, Inc. DXCM reported third-quarter 2024 ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over ...